Respiri (ASX:RSH) is taking a big step forward with an agreement for its Pharmacy Catalyst members to sell its wheezo asthma management device. (Image: Getty)
Health & Biotech
Special Report: Respiri (ASX:RSH) is taking a big step forward with an agreement for its Pharmacy Catalyst members to sell its wheezo asthma management device.
Under the program, pharmacists will work with asthma sufferers to review their conditions and, when appropriate, recommend the wheezo device to help patients manage their symptoms.
Respiri’s $99.50 wheeze-detecting device launched in October, based on strong clinical research.
“The foundation of every pharmacy should be a deep understanding of their customer and being able to provide relevant and timely advice and support,” says Pharmacy Platform managing director Michael Flannery.
“With wheezo, our pharmacy members can provide much needed support to asthma patients and their caregivers with the objective of improving asthma management and outcomes.
“Clearly there are still significant asthma patient management issues when the patient leave the care of their health care professional and we believe that this partnership with Respiri will help address this.”
Respiri chief executive and managing director Marjan Mikel says that asthma patients and caregivers will stand to benefit from Pharmacy Catalyst’s focus on individualised patient care.
“The Respiri team looks forward to working with Pharmacy Catalyst members with programs that assist with patient engagement and education,” he said.
Respiri said its wheezo device is being sold at three pharmacy groups and a number of independent stores – about 500 pharmacies across Australia, 10 per cent of the total market.
The company hopes to soon finalise discussions with several additional pharmacy groups, representing about 1,000 stores.
Respiri says that on average across Australia, 14 patients per day discuss their asthma management with their pharmacist.
This article was developed in collaboration with Respiri, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Health & Biotech
Health & Biotech
Health & Biotech
